IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
2024年3月22日 - 6:00AM
IMUNON, Inc. (NASDAQ: IMNN), a
clinical-stage drug-development company focused on developing
DNA-mediated immunotherapy and next-generation vaccines, announces
that the Company will host a conference call at 10:00 a.m. ET on
Thursday, March 28, 2024 to discuss financial results for the year
ended December 31, 2023 and provide an update on its clinical
development programs with IMNN-001, a DNA-based interleukin-12
(IL-12) immunotherapy in Phase 2 clinical development for the
treatment of first-line, locally advanced-stage ovarian cancer, and
on its PlaCCine modality, a proprietary mono- or multi-cistronic
DNA plasmid and a synthetic DNA delivery technology for the
expression of pathogen antigens in preclinical studies for the
development of next-generation vaccines.
To participate in the call, interested parties
may dial 866-777-2509 (Toll-Free/North America) or 412-317-5413
(International/Toll) and ask for the IMUNON 2023 Earnings Call. A
live webcast of the call will also be available here.
The call will be archived for replay until April
11, 2024, and can be accessed at 877-344-7529 (U.S. Toll Free),
855-669-9658 (Canada Toll Free) or 412-317-0088 (International
Toll) using replay access code 8601697. An audio replay of the call
will also be available here for 90 days.
About IMUNON
IMUNON is a clinical-stage biotechnology company
focused on advancing a portfolio of innovative treatments that
harness the body’s natural mechanisms to generate safe, effective
and durable responses across a broad array of human diseases,
constituting a differentiating approach from conventional
therapies. IMUNON is developing its non-viral DNA technology across
its modalities. The first modality, TheraPlas®, is developed for
the coding of proteins and cytokines in the treatment of solid
tumors where an immunological approach is deemed promising. The
second modality, PlaCCine®, is developed for the coding of viral
antigens that can elicit a strong immunological response. This
technology may represent a promising platform for the development
of vaccines in infectious diseases.
The Company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the Company is
entering a first-in-human study of its COVID-19 booster vaccine
(IMNN-101). We will continue to leverage these modalities and to
advance the technological frontier of plasmid DNA to better serve
patients with difficult-to-treat conditions. For more information
on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s filings with the
Securities and Exchange Commission. IMUNON assumes no obligation to
update or supplement forward-looking statements that become untrue
because of subsequent events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey
W. Church |
Kim
Sutton Golodetz |
Executive
Vice President, CFO |
212-838-3777 |
and
Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 4 2024 まで 5 2024
Imunon (NASDAQ:IMNN)
過去 株価チャート
から 5 2023 まで 5 2024